FERMENTALG : Annual General Meeting ratifies the co-option of Alain Godard to the Board of Directors

information fournie par Actusnews •19/06/2015 à 10:00

Libourne – 16 June 2015 – Fermentalg held its Annual General Meeting on Friday 12 June, during which the shareholders of the industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae notably ratified the co-option of Alain Godard as a director.

Agronomist and researcher, Alain Godard spent the majority of his career working for Rhône-Poulenc / Aventis. A graduate of the ENSAT Graduate School of Life Sciences of Toulouse, he joined Rhône-Poulenc Agrochimie in 1975 after working in Benin as a researcher for the Institut de Recherche pour les Huiles et Oléagineux (Institute for Research on Oils and Oleaginous Plants). Having held several executive positions, he was named Chairman and CEO of the company in 1991. In 1997, he was appointed to the Executive Committee of Rhône-Poulenc, overseeing operations for the Group's “Animal and Plant Health” division and its activities in Asia. In 1999, he played an active part in the merger between Rhône-Poulenc and Hoechst which led to the creation of Aventis where he served as Chairman of the Management Board of Aventis CropSciences and member of the Executive Committee before leaving the Group in 2001. Since then, Alain Godard has participated in the development of several “biotech” start-up companies as director or consultant.

Mr. Godard's co-option follows that of Mrs. Agnès Paillard, Chairman of the Board of Directors of the French National Institute for Industrial Property (Inpi), President of the Aerospace Valley competitiveness cluster and Vice-President responsible for regional innovation policy for Airbus Group France (see the press release published on 27 October 2014)

The details of the votes are available online on the company's website.

About Fermentalg

Founded in 2009 by Pierre Calleja, Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its 1 ^st industrial and commercial joint-venture for the production of Omega-3 oils rich in EPA and DHA as well as several other partnerships with leading industrial groups. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, visit the Fermentalg website at: www.fermentalg.com.